These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 29122992

  • 1. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.
    de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hellström-Lindberg E, Tatic A, Symeonidis A, Huls G, Cermak J, van de Loosdrecht AA, Garelius H, Culligan D, Macheta M, Spanoudakis M, Panagiotidis P, Krejci M, Blijlevens N, Langemeijer S, Droste J, Swinkels DW, Smith A, de Witte T, EUMDS Steering Committee.
    Haematologica; 2018 Jan; 103(1):69-79. PubMed ID: 29122992
    [No Abstract] [Full Text] [Related]

  • 2. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
    Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M.
    Haematologica; 2019 Mar; 104(3):497-504. PubMed ID: 30287621
    [Abstract] [Full Text] [Related]

  • 3. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
    Porter JB, Cappellini MD, Kattamis A, Viprakasit V, Musallam KM, Zhu Z, Taher AT.
    Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462
    [Abstract] [Full Text] [Related]

  • 4. Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome.
    Zipperer E, Post JG, Herkert M, Kündgen A, Fox F, Haas R, Gattermann N, Germing U.
    Ann Hematol; 2013 Dec; 92(12):1617-23. PubMed ID: 23842708
    [Abstract] [Full Text] [Related]

  • 5. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.
    Cui R, Gale RP, Zhu G, Xu Z, Qin T, Zhang Y, Huang G, Li B, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z.
    Leuk Res; 2014 May; 38(5):545-50. PubMed ID: 24598841
    [Abstract] [Full Text] [Related]

  • 6. Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.
    de Swart L, Hendriks JC, van der Vorm LN, Cabantchik ZI, Evans PJ, Hod EA, Brittenham GM, Furman Y, Wojczyk B, Janssen MC, Porter JB, Mattijssen VE, Biemond BJ, MacKenzie MA, Origa R, Galanello R, Hider RC, Swinkels DW.
    Haematologica; 2016 Jan; 101(1):38-45. PubMed ID: 26385212
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Detection of Hepcidin in transfusion dependent myelodysplastic syndrome patients and its clinical significance].
    Qin Y, Liu H, Ruan S, Cai YF, You XF, Song GQ.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):758-61. PubMed ID: 22339912
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
    Steensma DP, Gattermann N.
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):431-44. PubMed ID: 24507819
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.
    Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Iron overload in myelodysplastic syndromes (MDS).
    Gattermann N.
    Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.